Abzena logo

ABZA - Abzena Share Price

15.75p 0.0  0.0%

Last Trade - 10/10/18

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £22.0m
Position in Universe th / 1834
Bullish
Bearish
Unlock ABZA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ABZA Revenue Unlock ABZA Revenue

Net Income

ABZA Net Income Unlock ABZA Revenue

Normalised EPS

ABZA Normalised EPS Unlock ABZA Revenue

PE Ratio Range

ABZA PE Ratio Range Unlock ABZA Revenue

Dividend Yield Range

ABZA Dividend Yield Range Unlock ABZA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ABZA EPS Forecasts Unlock ABZA Revenue
Profile Summary

Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups. It offers immunogenicity assessment, which includes EpiScreen, iTope and T Cell Epitope Database (TCED); antibody drug conjugates, which includes ThioBridge linkers; antibody, which includes Composite Human Antibodies and Composite Proteins; optimization of pharmacokinetics, which includes TheraPEG, HiPEG conjugates PEG to poly-histidine motifs and CyPEG, and PolyPEG; cell line development, which includes Composite Human Antibody; process development, Good manufacturing practices (GMP) manufacturing, and small molecules. The Company's Abzena inside includes Composite Human Antibodies and ThioBridge Antibody Drug Conjugates (ADCs).

Directors
Last Annual March 31st, 2018
Last Interim March 31st, 2018
Incorporated March 25, 2014
Public Since July 10, 2014
No. of Shareholders: n/a
No. of Employees: 236
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange London Stock Exchange
Shares in Issue 214,893,379
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ABZA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to ABZA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.